3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
29
Rectal Neoplasms
8
Colonic Neoplasms
7
Carcinoma, Hepatocellular
7
Cholangiocarcinoma
5
Stomach Neoplasms
4
Neoplasm Metastasis
4
Neoplasms
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Solid Tumors
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Locally Advanced Colorectal Carcinoma
1
Liver Neoplasms
1
Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Cancer Metastatic
1
Interventions
Gemcitabine
15
Cisplatin
15
pembrolizumab
9
Oxaliplatin
7
durvalumab
5
Leucovorin
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
Platinum
4
Albumin-Bound Paclitaxel
4
1,2-diaminocyclohexaneplatinum II citrate
4
Trastuzumab
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Capecitabine
3
zanidatamab
2
fludarabine
2
Paclitaxel
2
Nivolumab
2
Folfox protocol
2
Docetaxel
2
Cyclophosphamide
2
Biopsy
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tivozanib
1
pertuzumab
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Folfox protocol
×
1 year
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled